The UK and US have reached a major commercial pact that will guarantee zero levies on UK medicine products being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This pledge ensures that tariffs on these vital products will stay at zero for a timeframe of three years.
This development comes after earlier threats to significantly raise import taxes on patented drug products, with potential rates mentioned as high as double the cost.
"This agreement with the UK strengthens the global environment for new treatments and introduces long-overdue fairness to American-British drug exports," a release said.
Economic Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the US, which is easily the primary destination for major British pharmaceutical firms.
Trade data indicate that in the year prior to last September, the UK sold drugs valued at £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that timeframe.
"This deal protects work, boosts funding and paves the way for the UK to emerge as a international leader for life sciences," a government official stated.
Detailed British Pledges
The deal entails several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to raise total public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments were more than twenty percent.
Broader Context
The pact takes place against a protracted row between the drug companies and the UK government over medicine costs and approval rates.
This friction were intensified by claims that US patients were paying significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while substantial expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
